All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
During the Psoriasis and Psoriatic Arthritis Hub Steering Committee meeting, key opinion leaders met to discuss differential diagnosis and the importance of early treatment in psoriasis and psoriatic arthritis as part of our editorial theme on delayed diagnosis. This recorded discussion was chaired by Peter van de Kerkhof, and featured Ulrich Mrowietz and Paolo Gisondi.
Differential diagnosis and the importance of early treatment in psoriasis and psoriatic arthritis
In this discussion, van de Kerkhof opens by highlighting some of the factors that feed into early treatment of psoriasis and psoriatic disease, and then the impact of a late diagnosis, focusing on the negative impacts on quality of life (QoL). He goes on to discuss the importance of early diagnosis to mitigate this decline in QoL and for long-term sustainable disease control.
Mrowietz closes the discussion by sharing the spectrum of psoriatic disease (Figure 1), discussing how early treatment can be used to target multiple aspects of psoriatic disease, including its comorbidities.
Figure 1. Psoriatic disease spectrum*
*Adapted from Mrowietz, et al.1
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox